What's in Apellis Pharmaceuticals, Inc.'s pipeline?

Apellis Pharmaceuticals, Inc. has 5 drugs in our index: 1 marketed, 0 filed, 2 in Phase 3, 1 in Phase 2, 1 in Phase 1.

Which companies overlap with Apellis Pharmaceuticals, Inc.'s portfolio?

Top competitors by shared drug class: Alexion Pharmaceuticals, Inc., Hoffmann-La Roche.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/apellis-pharmaceuticals-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-14 · How we verify

Apellis Pharmaceuticals, Inc. — Portfolio Competitive Intelligence Brief

Apellis Pharmaceuticals, Inc. pipeline: 1 marketed, 0 filed, 2 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 2 Phase 3 1 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Soliris	Soliris	marketed		Complement C5	Neuroscience
APL-2, Pegcetacoplan	APL-2, Pegcetacoplan	phase 3	Complement C3 inhibitor	Complement C3	Immunology / Rare Disease
APL-2	APL-2	phase 3	Complement C3 inhibitor	Complement C3	Immunology

Therapeutic area mix

Immunology · 2
Immunology / Rare Disease · 1
Neuroscience · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Alexion Pharmaceuticals, Inc. · 1 shared drug class
Hoffmann-La Roche · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Apellis Pharmaceuticals, Inc.:

Cite this brief

Drug Landscape (2026). Apellis Pharmaceuticals, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/apellis-pharmaceuticals-inc. Accessed 2026-05-14.